An Expanding List of Tier 1 Genomic Applications: Evidence-based Guidelines for Hypertrophic Cardiomyopathy and Public Health

Posted on by Michael A. Burke and Laurence S. Sperling, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, W. David Dotson and Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, Georgia

a heart in a body with the text: Tier 1 Genomic ApplicationsThe CDC Tier-Classified Guideline Database includes three Tier 1 guidelines on hypertrophic cardiomyopathy (HCM). A 2014 guideline from the European Society of Cardiology, a 2017 guideline from the American Heart Association, American College of Cardiology, and Heart Rhythm Society, and a 2020 guideline from the American Heart Association and American College of Cardiology all recommend genetic testing for patients meeting diagnostic criteria for HCM. Each includes recommendations for evaluation of family history, cascade genetic testing in relatives, and genetic counseling of affected individuals. Although there are currently no therapies available for primary prevention of HCM, identifying family members at increased genetic risk can help inform broader risk stratification and routine surveillance strategies. In this blog post we review recommendations for cascade genetic testing in HCM for public health.

HCM is an inherited heart disorder which results in abnormal thickening of the heart walls (hypertrophy) that can lead to heart failure (HF), atrial fibrillation, and sudden death due to ventricular arrhythmias. In up to 40% of affected people, HCM is caused by a specific change (mutation) in one of the genes that make up a structure called the cardiac sarcomere, which allows muscle cells to contract. Only one copy of a defective gene is needed to develop HCM (autosomal dominant).

HCM is common, affecting about 1 in 500 individuals (0.2%, or over 660,000 people in the United States). HCM is characterized by incomplete and age-dependent penetrance, with most individuals not developing manifest disease until adulthood. Genetic testing from the Framingham Heart Study and the Jackson Heart Study, 2 large, U.S., population-based epidemiologic studies, have shown that the prevalence of likely disease-causing sarcomere gene mutations may be as high as 0.6% (nearly 2 million individuals in the U.S.), suggesting the lifetime prevalence of HCM is higher than that estimated by clinical imaging.

Sudden death is the most concerning complication of HCM. Among those with HCM, sudden death occurs at an annual incidence of 0.6%, which is approximately 10-fold higher than in population-based cohorts; this would correspond to between 4,000-12,000 deaths every year in the U.S., depending on population prevalence between 0.2-0.6%. It is expected that nearly 1 in 6 patients with HCM will die suddenly. Further, HCM is a common cause of sudden death in children and young adults, a devastating complication reported in many high-profile cases of professional and amateur athletes. Notably, clinical risk stratification in those with HCM can guide the use of life-saving implantable cardioverter-defibrillator therapy.

In addition to sudden death, symptoms of HF occur with a lifetime incidence of ~70% in HCM, and approximately 5% of individuals will develop medically refractory HF that leads to premature death or the need for advanced HF therapies such as heart transplantation or a surgically implanted mechanical heart pump (left ventricular assist device, or LVAD). Finally, atrial fibrillation, a common cause of disabling strokes, occurs at a higher incidence in HCM relative to the general population, particularly in younger individuals. Importantly, stroke risk in HCM is independent of traditional risk stratification tools used for patients with atrial fibrillation. Therefore, early detection is of paramount importance as initiation of anticoagulant therapy to reduce stroke risk is advised for all patients with HCM and atrial fibrillation, a recommendation that differs from individuals without HCM who have atrial fibrillation.

Given the age-dependent penetrance of HCM, the risk of complications is highest in those with clinically evident cardiomyopathy earlier in life, potentially leading to decades of life lost to disability or early mortality. Recent data from the Sarcomeric Human Cardiomyopathy Registry (SHaRe), an international consortium of HCM centers of excellence and the largest cohort study of HCM to date, has shown that those diagnosed with HCM before age 40 have a ~90% lifetime chance of developing a significant HCM-related complication along with a ~30% lifetime chance of sustaining a potentially life-threatening ventricular arrhythmia. By comparison, those diagnosed after age 60 have a ~30% chance of a significant HCM-related complication with a ~1% risk of ventricular arrhythmias. This age-dependent risk is directly correlated with the presence of a sarcomere gene mutation.

The SHaRe consortium has also shown that sarcomere gene mutation-positive individuals are diagnosed with HCM at substantially younger ages (median age at diagnosis 37- vs. 51-years) and have a 2.2-fold higher incidence of HCM-associated complications than sarcomere gene mutation-negative individuals with HCM. Across all age groups, patients with HCM have 3-fold higher mortality than the general U.S. population. Importantly, this burden is highest in the young (4.3-fold increased risk of death in HCM patients aged 20-29 vs. an age-matched U.S. cohort) and is almost exclusively restricted to sarcomere gene mutation-positive individuals.

These findings highlight the large and potentially preventable burden of death and disability associated with HCM, particularly in sarcomere gene mutation-positive individuals. Consequently, the guidelines mentioned above recommend genetic testing for those with HCM to confirm the diagnosis and facilitate cascade genetic testing for their family members if a likely causative mutation is identified. The expanding list of tier 1 genomic applications in clinical practice points to the growing importance of genomics as a public health tool for identifying at-risk individuals, accelerating care to impact preventable events, and improving population health.

Posted on by Michael A. Burke and Laurence S. Sperling, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, W. David Dotson and Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaTags , ,

2 comments on “An Expanding List of Tier 1 Genomic Applications: Evidence-based Guidelines for Hypertrophic Cardiomyopathy and Public Health”

Comments listed below are posted by individuals not associated with CDC, unless otherwise stated. These comments do not represent the official views of CDC, and CDC does not guarantee that any information posted by individuals on this site is correct, and disclaims any liability for any loss or damage resulting from reliance on any such information. Read more about our comment policy ».

    The expansion of the list of Tier 1 genomic applications to include genetic testing for HCM is a welcome move by the CDC and the authors: hopefully this will give health insurance companies less excuse to deny coverage for genetic testing for HCM patients and family members.

    As a physician, I strongly support the addition of both cardiomyopathy and aortopathies to be listed in Tier 1 as it would greatly improve our ability to identify and prevent premature morbidity and mortality from these conditions.

Post a Comment

Your email address will not be published. Required fields are marked *

All comments posted become a part of the public domain, and users are responsible for their comments. This is a moderated site and your comments will be reviewed before they are posted. Read more about our comment policy »

Page last reviewed: October 6, 2021
Page last updated: October 6, 2021